Amoy Diagnostics Co (SZSE:300685) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is Amoy Diagnostics Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Amoy Diagnostics Co is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Amoy Diagnostics Co's Risk Assessment

For the Diagnostics & Research subindustry, Amoy Diagnostics Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amoy Diagnostics Co's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Amoy Diagnostics Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Amoy Diagnostics Co's Risk Assessment falls into.

Amoy Diagnostics Co (SZSE:300685) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Amoy Diagnostics Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Amoy Diagnostics Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Amoy Diagnostics Co (SZSE:300685) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Amoy Diagnostics Co Ltd (SZSE:300685) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

39 Dingshan Road, Haicang District, Xiamen, CHN, 361027

Website

http://www.amoydx.com

Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.

Executives

Ruan Li	Directors, executives
Zheng Hui Bin	Directors, executives
Chen Ying	Directors, executives
Luo Jie Min	Executives
Zhu Guan Shan	Directors, executives
Yang Shou Qian	Securities Affairs Representative
Zhou Wen Gang	Executives
Zhou Xue Lin	Independent director
Hu Xu Bo	Director

Amoy Diagnostics Co (SZSE:300685) Headlines

No Headlines